← Back to headlines
FDA Grants Rolling Review and CNPV Designation to Compass Pathways for TRD Treatment
Compass Pathways has received a Rolling Review and a Conditional New Product Vouchers (CNPV) designation from the FDA for its treatment targeting Treatment-Resistant Depression (TRD).
27 Apr, 06:21 — 27 Apr, 06:21
Sources
Showing 1 of 1 sources
